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Abstract—In various real-world applications, it is very useful
mining unanticipated episodes where certain event patterns unex-
pectedly lead to outcomes, e.g., taking two medicines together some-
times causing an adverse reaction. These unanticipated episodes
are usually unexpected and infrequent, which makes existing data
mining techniques, mainly designed to find frequent patterns, inef-
fective. In this paper, we propose unexpected temporal association
rules (UTARs) to describe them. To handle the unexpectedness,
we introduce a new interestingness measure, residual-leverage, and
develop a novel case-based exclusion technique for its calculation.
Combining it with an event-oriented data preparation technique
to handle the infrequency, we develop a new algorithm MUTARC
to find pairwise UTARs. The MUTARC is applied to generate ad-
verse drug reaction (ADR) signals from real-world healthcare ad-
ministrative databases. It reliably shortlists not only six known
ADRs, but also another ADR, ﬂucloxacillin possibly causing hep-
atitis, which our algorithm designers and experiment runners have
not known before the experiments. The MUTARC performs much
more effectively than existing techniques. This paper clearly illus-
trates the great potential along the new direction of ADR signal
generation from healthcare administrative databases.
Index Terms—Adverse drug reaction (ADR), data mining,
healthcare administrative databases, pharmacovigilance, unantic-
ipated episode, unexpected temporal association.
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I. INTRODUCTION
IN VARIOUS real-world applications, it is quite useful to findunanticipated episodes where event patterns unexpectedly
lead to outcomes. For example, users unexpectedly turn to use
Yahoo! search engine after navigating through a topic path in
Yahoo! Web directory, which may imply a difficulty on finding
Web content pages by following the topic path. Another exam-
ple is taking the drug rofecoxib to relieve signs and symptoms
of arthritis, but then unexpectedly experiencing myocardial in-
farction [1]. Detecting these unanticipated episodes is of great
value in correction or prevention, especially if outcomes are
life threatening. Due to unexpectedness, such an episode may
not necessarily occur as an event pattern confidently implying
an outcome as in temporal association rules (TARs) [2], [3] or
sequential patterns [4]–[6]. In addition, unanticipated episodes
normally occur infrequently, otherwise they become expected.
The infrequency makes existing frequent itemsets/sequential
patterns mining techniques ineffective. Thus, finding these un-
expected and infrequent episodes necessitates innovative knowl-
edge representations and mining techniques. In this paper, we
introduce unexpected temporal association rules (UTARs) to de-
scribe these unanticipated episodes, and provide an algorithm
for discovering them.
Promptly generating adverse drug reaction (ADR) signals
from healthcare administrative databases provides a real-world
example to illustrate the usefulness of our techniques. As rec-
ommended by the International Committee on Harmonization
(ICH), “all noxious and unintended responses to a medicinal
product related to any dose should be considered ADRs. The
phrase ‘responses to a medicinal product’ means that a causal
relationship between a medicinal product and an adverse event
is at least a possibility [7].” Most ADRs are infrequent. Such
low incidence is of course expected due to the fact that drugs
are tested prior to release onto the market. However, due to
limited patient numbers and trial duration of this screening pro-
cess, ADRs with incidence rates less than 0.1% are normally
not detected [8], [9], such as myocardial infarction caused by
rofecoxib [1]. As a whole, e.g., it is estimated that millions of
patients are hospitalized due to adverse events in the USA each
year [10] and more than 80 000 in Australia [11]. ADRs are
a major cause of morbidity and mortality worldwide [10], and
30%–60% ADR cases are believed to be preventable by careful
prescribing and monitoring [12]. Thus, such ADR patterns as
a drug probably causing a symptom/condition, can play a key
role in the prevention or correction. Using these ADR patterns,
e.g., computerized systems can search health records to monitor
1089-7771/$25.00 © 2008 IEEE
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adverse events [12], to find patient groups at risk [13], and to
help general practitioners (GPs) ameliorate their diagnoses and
prescriptions [8].
Existing postmarket ADR detection techniques, known as
signal generation in pharmacovigilance, mainly work on spon-
taneous ADR case reports, submitted voluntarily by medical
practitioners about observed suspected causalities between
drug usage and adverse reactions [9]–[14]. However, in sponta-
neously reporting systems like the Australian ADR Reporting
System [15], medical practitioners significantly underreport
ADR cases, typically by a factor of about 20 [12], [16]. Adverse
reactions may go unnoticed until large numbers of users have
been affected [17]. In contrast, healthcare administrative data
routinely record events about patients’ interactions with a
healthcare system for management and accounting purposes. In
Australia, e.g., almost all medical services for almost entire pop-
ulation are included in these databases [18]. It is desirable to de-
velop techniques to promptly and systematically signal (and then
validate) ADRs from these databases. They can complement the
existing postmarket ADR detection techniques, especially on
rare ADRs resulting in serious outcomes such as hospitalization
or disability. Our proposed techniques make a successful
attempt to signal ADRs from healthcare administrative data,
which is a brand new ADR signal generation direction in the
literature.
We propose UTAR, denoted by A T↪→C, to describe an unan-
ticipated episode where an event pattern A unexpectedly occurs
in a T-sized period prior to another event pattern C. The pe-
riod length T constrains the temporal relation between the an-
tecedent A and the consequent C, and so, ensures the UTARs’
plausibility. To handle the unexpectedness, we introduce an in-
terestingness measure, residual-leverage and give a case-based
exclusion technique for its calculation. The basic idea is to ex-
clude “expected” events in individual T-sized subsequences, and
then, aggregate unexpectedness over all the remaining T-sized
subsequences. We further use an event-oriented data preparation
technique to handle the infrequency. We then establish a new al-
gorithm, MUTARC, to discover pairwise UTARs. Our proposed
techniques are in principle extendible to longer patterns, such as
drug–drug interactions causing symptoms. We apply MUTARC
to signal ADRs from a healthcare administrative data set of
prescribed drugs and diagnoses. It shortlists six known ADRs
and another ADR, ﬂucloxacillin T↪→ hepatitis, that has been
previously unknown to our algorithm designers and experiment
runners before the experiments. The MUTARC also empirically
outperforms OPUS_AR+ (extended from OPUS_AR [19]) for
signaling ADRs. Medical experts believe that the proposed tech-
niques are promising in the brand new direction of ADR signal
generation.
The rest of the paper is organized as follows. We pro-
pose UTARs to represent unanticipated episodes in Section II,
and establish the MUTARC to discover the most interest-
ing UTARs in Section III. Typical results and reliability ex-
amination are presented in Section IV. Related work is dis-
cussed in Section V, followed by concluding comments in
Section VI.
Fig. 1. Illustration of temporal event sequences and T-constrained subse-
quences. Di and Hj indicate different categories of event types. For example,
Di indicates taking drug i, while Hj indicates an occurrence of condition j in
healthcare administrative databases.
II. PROBLEM FORMULATION
We first characterize the concept of unanticipated episodes.
We assume that a number of subjects have their own sequences
of events, each of which is a list of event types together with
their timestamps as exemplified in Fig. 1. For simplicity, we
use event and event type interchangeably hereafter. The effect
of most types of events normally lasts for a short period of time,
e.g., a Web visit session lasts minutes to hours, and drug usage
usually produces adverse events within weeks to months [8]. We
introduce a period length T to consider limited effect periods of
related events in order to ensure the plausibility of unantici-
pated episodes. Then, an unanticipated episode involves two
event patterns A and C such that A is unexpectedly followed
by C relatively frequently within the T-sized periods. Relatively
high frequency is emphasized because it is practicable to de-
sign algorithms to identify them from large real-world data that
usually contain some noises, such as healthcare administrative
data [18]. In addition, such an unanticipated episode is applica-
ble to more subjects and, as knowledge, is of more value. Both
A and C can be existence patterns (i.e., a set of events) or se-
quential patterns (i.e., an ordered list of events). For simplicity,
we will only discuss existence patterns hereafter.
We then try to use TARs to describe these unanticipated
episodes. Association rules are implications in the form of
A → C, meaning that the presence of A implies the presence
of C, where A and C are mutually disjoint [20]. By embedding
temporal constraints into association rules, we suggest a
category of TARs denoted by A T→C. The notation T→ is
used to indicate explicitly that the antecedent A and/or the
consequent C occur within subsequences constrained by time
windows of length T. To simplify temporal constraints, we only
choose one subsequence within a T-sized time window from
each sequence, and call it T-constrained subsequence. The
T-constrained subsequences for patients 1 and 2 in Fig. 1, e.g.,
are {D1 ,D3 ,D5 ,D6 ,H1} and {D4 ,D5 ,D8 ,H2 ,H3}, respec-
tively. Given a set of T-constrained subsequences ΘT , the sup-
port of a TAR supp(A T→C) is the proportion of T-constrained
subsequences in which A occurs prior to C at least once. For
the four subsequences in Fig. 1, e.g., supp(D1D6
T→H1) =
2/4. Similarly, its confidence conf (A T→C) =
supp(A T→C)/supp(A T→ ), where supp(A T→ ) indicates
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the proportion of T-constrained subsequences that contain A
in ΘT . As another measure of association strength [19]–[21],
leverage can be defined as the proportion of T-constrained sub-
sequences that exhibit the association between the antecedent A
and the consequent C in excess of those that would be expected
if A and C were independent of each other. That is,
leverage(A T→C)= supp(A T→C)− supp(A T→) ·supp( T→C)
(1)
where supp( T→C) indicates the proportion of T-constrained
subsequences that contain C in ΘT . For the four T-constrained
subsequences in Fig. 1, e.g., leverage(D1D6
T→H1) = 2/4−
2/4× 2/4 = 1/4. Similarly, leverage(D1 T→H1) =
leverage(D6
T→H1) = 1/4. D1 and D6 have the same
association strength with respect to H1 based on leverage. Us-
ing (1) and noting that 0 ≤ supp( T→C) and supp(A T→ ) ≤ 1,
we have the following inequality between the three measures:
leverage(A T→C) ≤ supp(A T→C) = conf (A T→C). (2)
There are two different strategies for mining TARs in or-
der to discover unanticipated episodes. The first one is to find
valid TARs whose support and confidence exceed prespecified
thresholds θs and θc , respectively [20]. The second one is to
find the most interesting rules based on some interestingness
measure [19].
As discussed in Section I, unanticipated episodes including
ADRs in pharmacotherapy occur normally at low frequency
because of their unexpectedness as well as human regulatory
processes. Thus, there are several drawbacks for the first strat-
egy.
1) The support threshold θs and the confidence threshold θc
should be set very small. This leads to innumerable valid
TARs, and makes any mining algorithms unmanageable
and the computation cost disproportionally high [20].
2) It will generate overwhelming volume of possibly useless
results.
3) It is still not easy to set these threshold values appropriately
[19].
Thus, it is quite complicated to identify unanticipated episodes
from valid TARs. The situation is similar for other temporal data
mining models, e.g., sequential patterns [4]–[6] or event-driven
sequential patterns [22], [23].
Following the second strategy, we can identify unanticipated
episodes through shortlisting most interesting rules. We may,
e.g., simply apply OPUS_AR [19] on the T-constrained
subsequence set ΘT to generate the most interesting TARs. We
call this algorithm OPUS AR+ . It can return a prespecified
number of TARs that maximize an association quality measure
such as leverage.
The existing interestingness measures, such as support,
confidence, risk ratio, odds ratio [8], lift, leverage [19],
etc., are not suitable for highlighting TARs for detecting
unanticipated episodes. As discussed earlier, due to their
infrequency and unexpectedness, supports and confidences
for TARs corresponding to unanticipated episodes are
normally low. It seems impracticable to identify unantic-
ipated episodes by choosing TARs with high support or
confidence. The risk and the odds ratios appeal to domain
experts, and are commonly used in effect evaluation [16].
For example, the risk ratio for A T→C is RR(A T→C) =
[supp(A T→C)/supp(A T→ )]/[supp(¬A T→C)/supp(¬A T→ )],
where ¬A indicates that A does not occur. This describes
the degree to which, within the T-constraint, the occurrence
of C increases with the occurrence rate of A. However, the
risk and the odds ratios are not suitable for detecting unan-
ticipated episodes like ADRs from healthcare administrative
databases. The first reason is that they have been widely used
in effect evaluation, especially premarket drug testing; so,
drugs having high risk or odds ratios may not be approved
to release onto the market. Thus, the risk or odds ratios for
ADRs in healthcare administrative databases are relatively
low. This, as also empirically shown in Section IV, makes
them inappropriate for highlighting unanticipated episodes like
ADRs. The second reason is that, due to data noises, biases, or
incompleteness,1 the ranking based on these ratios may not be
reliable. This point is also applicable to lift that may be defined
as lift (A T→C) = supp(A T→C)/supp(A T→ )supp( T→C).
Furthermore, leverage can not express the unexpectedness
that we need for detecting unanticipated episodes. Based on
the leverage values, e.g., paracetamol (N02BE01 in Tables II
and VI in Section IV-B is found to be strongly associated
with two conditions, esophagitis and angioedema. However,
paracetamol is widely used in the treatment of mild to
moderate pain and fever, and may have been given as part of
the treatment for these two conditions. These associations are
not unexpected.
Thus, we need to introduce a knowledge representation for
unanticipated episodes. Our strategy is to embed unexpected-
ness into rules directly. To clearly indicate temporal unexpected-
ness, we introduce an UTAR, denoted by A T↪→C, which means
that the antecedent A occurs unexpectedly within a T-sized pe-
riod prior to the consequent C. Rather than defining unexpect-
edness explicitly, we aggregate it from individual sequences.
Definition 1: The support of the UTAR, supp(A T↪→C), is
the proportion of T-constrained subsequences that unexpect-
edly contain A followed by C among all of the T-constrained
subsequences. Its confidence is given by conf (A T↪→C) =
supp(A
T
↪→C)/supp(A T↪→), where supp(A T↪→) is the propor-
tion of T-constrained subsequences that unexpectedly containA.
According to Definition 1, only the subsequences that un-
expectedly contain A will contribute to support or confidence
of A T↪→C. There exist various ways to check whether A is un-
expectedly contained in a subsequence. Instead of judging this
directly, we may remove “expected” event types and roughly
keep others as “unexpected ones.” For example, if we know
that a drug A is prescribed to treat a condition C, A can
1For example, the Queensland Linked Data Set, which is used for testing this
research, does not contain any other symptoms/conditions/diagnoses except
diagnoses from inpatient episodes during a 4-year period. It does not contain
any drug prescriptions within inpatient episodes [18], [24].
Authorized licensed use limited to: University of Adelaide Library. Downloaded on December 2, 2009 at 00:07 from IEEE Xplore.  Restrictions apply. 
JIN et al.: MINING UNEXPECTED TEMPORAL ASSOCIATIONS: APPLICATIONS IN DETECTIN ADRs 491
be removed for the purpose of finding ADRs with respect to
C, as C is not unexpected with respect to taking A. Another
example is, for patient 1 in Fig. 1, a drug D1 is taken frequently
within a T-sized period prior to, and also, far before the unique
condition H1 , and it is difficult to say that this sequence favors
the unexpected temporal association D1
T
↪→H1 without prior
knowledge. But D5 and D6 only occur just before H1 , and it is
reasonable to say that this sequence favors D5D6
T
↪→ H1 . Thus,
the sequence information outside of a subsequence can be used
to prune “expected” event types. The remaining subsequences
can then be aggregated together to express the unexpectedness
of UTARs. For the four subsequence in Fig. 1, e.g., we can have
supp(D1
T
↪→H1) = 1/4 while supp(D1 T→H1) = 2/4. A pos-
sible calculation method based on a simple case-based exclusion
operation will be given in Section III.
Note that 0 ≤ supp(A T↪→ ) ≤ 1, we have
supp(A
T
↪→C) ≤ supp(A T→C) (3)
supp(A
T
↪→ ) ≤ supp(A T→ ) (4)
supp(A
T
↪→C) ≤ conf (A T↪→C). (5)
We now introduce a new interestingness measure, residual-
leverage.
Definition 2: The residual-leverage (resilev) of the UTAR,
A
T
↪→C, is the proportion of T-constrained subsequences that
exhibits the unexpected association between A and C in excess
of those that would be supposed if unexpected A and C were
independent of each other. That is
resilev(A
T
↪→C)=supp(A T↪→C)−supp(A T↪→)×supp( T→C).
(6)
It intuitively indicates the degree to which the observed un-
expected associations between A and C exceeds supposed asso-
ciations based on an independence assumption. It considers ob-
served unexpected associations between A and C, while lever-
age considers observed associations between them. We have
conf (A
T
↪→C) ≥ supp(A T↪→C) ≥ resilev(A T↪→C). (7)
Similar to support and confidence, we can set a threshold
for residual-leverage to define a valid UTAR. This threshold
may increase the likelihood of finding interesting UTARs. Once
again, the number of such valid UTARs can be too large if the
threshold is set too low. Conversely, really interesting UTARs
are missed if it is set too high.
To relieve the problem of setting thresholds completely, we
simply select a prespecified number of, say ten, UTARs with
the highest residual-leverage values. The second reason to
rank UTARs only according to residual-leverage is that large
residual-leverage also indicates large support and confidence as
indicated by (7) and
conf (A T→C) ≥ supp(A T→C) ≥ supp(A T↪→C)
≥ resilev(A T↪→C). (8)
The inequality in (8) is based on (2), (3), and (7). This guar-
antees that the generated UTARs will have reasonable support,
and they will correspond better with relatively frequent unan-
ticipated episodes, as discussed at the beginning of this section.
In addition, large residual-leverage will also imply large lever-
age, as shown in Theorem 1 in Section III, when the case-based
exclusion operation is used.
III. SEARCHING FOR UNEXPECTED TEMPORAL
ASSOCIATION RULES
In this section, we develop a simple but effective algorithm to
search for the most interesting UTARs. We concentrate on pair-
wise UTARs, such as an ADR, where one single drug possibly
induces one condition, i.e., drug A T↪→ condition C. Such pair-
wise UTARs are of great application value, and some successful
experience with them can pave the way for us to discover more
sophisticated UTARs in the future.
Our proposed algorithm, the MUTARC, is outlined in
Algorithm 1.
Algorithm 1: Mining UTARs given the Consequent
(MUTARC)
1) initialize parameters, such as the consequent C, event
types of interest, the study period [tS , tE ], time period
lengths Th, Tr , Tb , and Tc, and the number of output
UTARs k;
2) prepare case subsequences from case sequences that have
the first occurrence of C during the study period: for each
case, choose events within its hazard period, and exclude
some of them based on the case-based exclusion with
respect to the consequent C;
3) choose noncase subsequences within control periods from
noncase sequences;
4) calculate supports and residual-leverage of each event; and
5) rank the events in the descending order of residual-
leverage, and return the top k interesting UTARs.
Its basic idea is to choose subsequences around a given conse-
quent, remove “expected” events according to a case-crossover
design, and then, calculate residual-leverage values. The tech-
niques for mining UTARs around a given antecedent are dis-
cussed in [24]. We take the sequences in Fig. 1 as examples to
explain MUTARC later.
First, we initialize parameters that are explained as follows.
1) The consequent C is specified to restrict the search space
so as to facilitate mining unanticipated episodes. The se-
quences containing C are called case sequences while
other sequences are called noncase sequences. In Fig. 2,
e.g., H1 is specified, and then, patients 1 and 3 in Fig. 1
are cases and patients 2 and 4 are noncases, respectively.
2) Event types of interest are to limit the possible candidates
for the antecedent A, e.g., D1 −D8 in Fig. 2.
3) A study period is determined by [tS , tE ]. A case sequence
whose first occurrence of the consequent C is not in the
study period will simply not be considered. We restrict
ourselves to the first occurrence in this paper in order to
facilitate the implementation of the case-based exclusion
and choosing at most one T-constrained subsequence for
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Fig. 2. Illustration of the event-oriented data preparation and case-based ex-
clusion in the MUTARC.Di andHj indicate a drug-taking event and a condition
occurrence, respectively. H1 indicates the specified consequent in this example.
each case sequence. Another reason is that there is only a
small population of patients with multiple occurrences of
the consequence C in the data set that we will study.
4) The time lengths Th, Tr , Tb , and Tc indicate, as illustrated
in Fig. 2, the hazard period length, the reference period
length, the period length between the hazard and the refer-
ence periods, and the control period length, respectively.
We set the hazard period for each case sequence as the Th -
sized period before the first occurrence of the consequent C that
occurs in the study period. Clearly, the events within the hazard
period might cause the consequent C. Among them, some are
less likely to unexpectedly lead to C. If domain experts can
provide a list of event types that do not unexpectedly lead to
C, we may simply exclude them from the case subsequences.
But, such kind of domain knowledge is often unavailable or
out of date [25]. Fortunately, for each case sequence, we can
use the events that occurred outside of the hazard period to
deduce some event types that do not unexpectedly lead to C.
For example, if an event occurs repeatedly in the case sequence,
say, if the subject often takes one drug like D1 for Case 1 in
Fig. 2, this event is less likely to induce the first occurrence of
the consequent C. The underlying reason is that most events,
such as taking a drug, have short-term effects [26], and the
subject has similar responses to a certain event. Thus, we may
disregard this event from the subsequence, and deduce that the
remaining ones are more likely to induce C unexpectedly. This
exclusion operation is carried out only based on a single case
sequence, and is termed as case-based exclusion. To further
simplify this exclusion operation, we borrow the concept of the
reference period from case-crossover studies [26]. The reference
period is a Tr -sized period that is a Tb -sized interval before the
hazard period as illustrated in Fig. 2. If the event (e.g., taking
a drug) in the reference period is protective/therapeutic to the
consequent C, the subject is not surprised about the occurrence
of C. In contrast, the subject (or his/her GPs) will believe that the
events within the reference period are basically “safe” to him/her
because there is no occurrence of an unexpected outcome, like
C, even long after the reference period. Thus, the events within
the reference period are probably expected to the subject with
respect to the consequent C, and they can be excluded for mining
UTARs. For case 1 in Fig. 2, e.g., {D1 ,D2 ,D3 ,D4} are in the
reference period, and {D1 ,D3 ,D5 ,D6} in the hazard period.
D1 and D3 are excluded, and only {D5 ,D6} are kept for the
subsequence for case 1. Similarly, {D1 ,D6 ,D7} are left for
case 2.
In Step 3 of the MUTARC, for each noncase sequence, we
have two different methods to set a Tc -sized control period
in order to choose a noncase subsequence. We may randomly
choose the control period within [tS − Tc, tE ]. The other one is
motivated by matched case-control studies [8] in order to avoid
some possible impact from other factors such as age, gender, and
seasonality. We set the control period to match a case according
to, say, demographic data. A noncase is chosen from the same
demographic (e.g., age-gender) stratum as the case. In addition,
the noncase has an event similar to C that also occurs temporally
closely to C in the case, say, the onset of another condition in
the same month of the onset of the condition C. For example,
noncase 1 in Fig. 2 has H3 that occurs in the same month
with H1 of case 1; thus, the Tc -sized period before H3 is set
as the matched control period for noncase 1. With respect to
case 2, the matched control period for noncase 2 is the Tc -sized
period before H4 . The events within the control periods, say,
D4 ,D5 , and D8 for noncase 1, and D4 for noncase 2, compose
noncase subsequences. These noncase subsequences roughly
provide baseline frequency information for these event types.
In Step 4, putting these case subsequences after exclusion
and these noncase subsequences together, we then calculate
supports for each event with respect to C. Now supp(A T↪→C)
takes into account only the case subsequences that more likely
unexpectedly contain A followed by C. We then compute
the residual-leverage value of each event according to (6).
We simply assume that a noncase subsequence “unexpect-
edly” contains A once it contains A. For the four sequences
in Fig. 2, e.g., resilev(D1
T
↪→H1) = supp(D1 T↪→H1)−
supp(D1
T
↪→ )× supp( T→H1) = 1/4− 1/4× 2/4 = 1/8
and resilev(D6
T
↪→H1) = 2/4− 2/4× 2/4 = 1/4. Thus,
residual-leverage roughly indicates the situation where D6 is
more unexpectedly associated with H1 than D1 .
Finally, the algorithm outputs the k most interesting event
types. Together with the consequent C, we have the k most
interesting UTARs.
In the MUTARC, the hazard and the control periods are set
according to the consequent C, and restrict the events in the
calculation of supports. This event-oriented data preparation
makes it possible to highlight the usually infrequent UTARs.
The case-based exclusion in Step 2 is designed to prune ex-
pected events from a case’s viewpoint. It is simple and easy for
implementation, but it plays a key role in the good performance
of the MUTARC. To highlight its contribution, we implement
and parameterize OPUS_AR+ same as MUTARC except with-
out the case-based exclusion operation. That is, the only differ-
ence between them is with or without the operation. Then, we
compare MUTARC and OPUS AR+ comprehensively. The fol-
lowing theorem indicates that, using this case-based exclusion,
the residual-leverage value is not greater than the leverage value.
Theorem 1: With the case-based exclusion, resilev(A T↪→C)
≤ leverage(A T→C).
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Proof: Let the proportion of case subsequences where A is
excluded be suppex(≥ 0). Because of the case-based exclusion,
we observe
supp(A T→C)− supp(A T↪→C) = suppex and (9)
supp(A T→ )− supp(A T↪→ ) = suppex . (10)
Considering the definition of support, we have another inequal-
ity 0 ≤ supp( T→C) ≤ 1.0. Simply, according to the definitions
of residual-leverage and leverage, we have
leverage(A T→C)− resilev(A T↪→C) = supp(A T→C)
− supp(A T↪→C)− (supp(A T→ )− supp(A T↪→ ))
× supp( T→C) = suppex − suppex × supp( T→C) ≥ 0.
(11)
The proof is completed. 
Combining Theorem 1 with (2), we also have
conf (A T→C) ≥ supp(A T→C) ≥ resilev(A T↪→C). This the-
orem says that large residual-leverage indicates large
confidence. For example, if resilev(A T↪→C) ≥ θ, then
leverage(A T→C) ≥ θ, too. Thus, as discussed in Section II,
we can simply choose the most interesting UTARs only based
on residual-leverage, and relieve the problem of setting appro-
priate thresholds.
IV. EXPERIMENTAL SETTING AND RESULTS
A. Linked Healthcare Administrative Data: The QLDS
The Commonwealth Scientific and Industrial Research Or-
ganization (CSIRO), through its Division of Mathematical and
Information Sciences, was commissioned by the now Australian
Government Department of Health and Ageing (DoHA) in Au-
gust 2002 to analyze a linked data set produced from Medi-
care Benefits Scheme (MBS), Pharmaceutical Benefits Scheme
(PBS), and Queensland hospital morbidity data, more com-
monly referred to as the Queensland Linked Data Set (QLDS)
[18]. The objective was to provide a demonstration of the utility
of data mining on deidentified administrative health data to in-
vestigate patterns of utilization, adverse events, and other health
outcomes.
The QLDS was made available to CSIRO under a negotiated
agreement between the DoHA and Queensland Health. The data
set contained deidentified and confidentially linked patient level
hospital separation data (July 1, 1995 to June 30, 1999), MBS
data and PBS data (both January 1, 1995 to December 31, 1999).
All data were deidentified, and actual dates of service were
removed, so that time sequences were indicated only by time
from first admission that was perturbed up to 16 days. This
process provided strong privacy protection, consistent with the
requirements of the relevant Federal and State legislations. The
CSIRO held the QLDS in a secure computer environment and
limited access to authorized staff directly involved in the data
analysis.
The QLDS provides a real-world data set appropriate for
testing the proposed techniques to generate ADR signals. Each
record in the hospital separation data corresponds to one inpa-
tient episode, and each diagnosis is coded in the International
Classification of Diseases, 9th revision, Clinical Modification
(ICD-9-CM) system, e.g., 530 is for esophagitis. Each record
in the MBS data corresponds to a medical service for one pa-
tient. Similarly, each record in the PBS data corresponds to
one prescription drug supplied to one patient, and the 3842
distinct prescription items are mapped into 758 distinct codes
in the WHO anatomical therapeutic chemical (ATC) classi-
fication system [27]. For example, the ATC codes for alen-
dronate,2 nefazodone,3 and Angiotensin Converting Enzyme
(ACE) inhibitors4 are M05BA04, N06AX06, and C09AA??5
respectively [27]. The QLDS contains records for 1 176 294 pa-
tients. For convenience, we refer to January 1, 1995 as the first
day hereinafter. Thus, the time period for the whole data set is
[1, 1826].
To speed up data access, for each patient, a temporal event
sequence was generated to record sequentially his/her hos-
pitalization, PBS, and MBS events, as well as their times-
tamps. The head of each sequence also included demographic
data such as age and gender. These sequences were strati-
fied into six age-gender strata according to their demographic
data. Ages were stratified into young ([0, 20), middle-aged
([20, 59]), and older (59) groups. Thus, we directly accessed
these sequences rather than the three linked administrative
databases in the QLDS. Both the MUTARC and OPUS AR+
were implemented in Python. All experiments were run un-
der Linux on a machine with an Intel Pentium 4 3.2 GHz
processor.
B. Typical Experimental Results
We first describe typical results generated by the MUTARC.
To highlight the significance of the case-based exclusion oper-
ation, we compare the MUTARC with OPUS AR+ where the
only difference is without the operation. We concentrate on three
types of diagnoses, esophagitis, hepatitis, and angioedema,
which are suspected to be sometimes induced by alendronate,
nefazodone, and ACE inhibitors, respectively [15], [28]. These
are all the ADRs that our algorithm designers and experiment
runners (all the authors except Chris) have known before these
experiments.
Like other data mining results, it is unrealistic to expect every
highly ranked UTAR to be of value or significance to domain
experts, especially considering the intrinsic data biases, noises,
2 Alendronate (Fosamax) is an aminobisphosphonate, which specifically
inhibits osteoclast-mediated bone resorption. It was approved for treatment of
osteoporosis in postmenopausal women and Paget’s disease of bone [28].
3Nefazodone, (Serzone) is one of the new antidepressants. It was marketed
in mid-1997 and withdrawn in 2004 in Australia. It is related to the selective
serotonin reuptake inhibitors (SSRIs), a widely used group of antidepressants),
but has a dual action in that it works on both sides of the serotonin synapse [15].
4 ACE inhibitors (ACE inhibitors) are a commonly used treatment of high
blood pressure and heart disease [29].
5Here, “?” is a wildcard. There are about nine different ATC codes for
ACE inhibitors, from C09AA01 to C09AA10 except C09AA07. For example,
C09AA03 represents lisinopril [27].
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TABLE I
TOP TEN DRUGS UNEXPECTEDLY ASSOCIATED WITH Esophagitis SHORTLISTED BY MUTARC FOR OLDER FEMALE PATIENTS (THE BOLD ROW IS FOR THE
SUSPECTED DRUG Alendronate)
and incompleteness of the QLDS1 [18]. One realistic goal is
to reliably shortlist the unexpected associations between pre-
scribed drugs and diagnoses among the 10 or 20 highest ranked
UTARs. These shortlisted UTARs can be regarded as ADR hy-
potheses, and have to be further evaluated and validated by
pharmacovigilance experts [8], [9]. For example, statistical tests
like Fisher exact test on independent data can help us remove
UTARs caused by biases or noises. We only discuss those results
consistent with existing domain knowledge in this paper.
As for the parameters of the MUTARC and OPUS_AR+ ,
we set Th = 180, Tr = 3Th, Tc = Th, and Tb = 365 in days
by default. Th and Tc were set as about six months for acute
or subacute ADRs [8]. Tb was set as about 1 year in order to
eliminate seasonality in drug usage. We set the study period as
[730, 1645], where 1645 is for the last hospitalization event in
the QLDS. For esophagitis, we focused on the older female
group, because 9092 out of 33094 esophagitis patients are fe-
male and older. For each older female esophagitis patient, we
chose up to six (only five are available for some of them) differ-
ent matched non-esophagitis patients who were from the same
age-gender group as the esophagitis patient and hospitalized
in the same month as the esophagitis onset. There were 49080
non-esophagitis subsequences. Then, the total number of sub-
sequences N was 58172. For 2912 hepatitis patients, we were
interested in 1034 middle-aged female hepatitis patients. We
chose up to 21 matched non-hepatitis subsequences for each
of them and got 21660 non-hepatitis subsequences in total. For
286 angioedema patients, we focused on 75 female and 41
male angioedema patients older than 59. Up to 21 matched
non-angioedema patients were chosen for each of them. There
were 1515 female and 795 male non-angioedema patients, re-
spectively.
Table I lists the top ten drugs having the highest residual-
leverage values with respect to esophagitis generated by the
MUTARC for the older female patients. After the case-based ex-
clusion, there are 186 (= supp(A T↪→C)×N) esophagitis pa-
tients from 628 (= supp(A T↪→ )×N) alendronate drug users.
Comparing the supports listed in Table II where some drugs
are ranked based on leverage generated by the OPUS_AR+ ,
we can observe that there are only 53 (= 239− 186) patients
taking alendronate within both reference and hazard peri-
ods. The UTAR alendronate T↪→ esophagitis has the residual-
leverage of 1.51× 10−3 , and, based on this, is ranked as 4
among 758 different kinds of drugs. As a comparison, the TAR
alendronate T→esophagitis is ranked as low as 31 in Table II.
This is partially because there are only 239 older female pa-
tients who took alendronate within their hazard periods, which
is much smaller than other drug users in Table II. The support
for this TAR is 0.41%, and it is ranked as low as 91. Though its
confidence is as high as 35.1% (due to the event-oriented data
preparation), this association is ranked as low as 43 based on the
confidence value. Its risk ratio is 2.279. It means an older female
patient, if taking alendronate, is about 2.279 times more likely
to suffer from esophagitis. The rank simply based on the risk
ratio is 44. Thus, the residual-leverage can highlight this ADR
much better than these other measures. Similar situations can
be observed for the other ADRs. On the other hand, paraceta-
mol (N02BE01) is ranked as no. 6 based on its leverage value,
and is thought to be strongly associated with esophagitis, as
shown in Table II. According to residual-leverage, it is ranked
as low as 546, because about 82.2% cases took paracetamol
in the reference periods. Note that similar interesting situations
happen with several therapeutic drugs like ranitidine, famoti-
dine, and aluminium hydroxide in Table II. Furthermore, the
MUTARC had a runtime of 57.2 s that is only 3.3 s longer than
OPUS_AR+ . These comparisons empirically support the pro-
posed measure, residual-leverage, is useful in removing some
protective/therapeutic drugs6 automatically and effectively for
ADR signal generation.
With respect to hepatitis for the middle-aged female pa-
tients, Table III lists the ten drugs having the highest residual-
leverage values generated by the MUTARC, while Table IV
lists drugs having the highest leverage values generated by
6Besides the simplified design of the case-based exclusion in the MU-
TARC and the data quality issues like noises, biases, and incompleteness1 ,
there exists another interesting reason why the MUTARC cannot remove
all protective/therapeutic drugs from the shortlisted UTARs: “treatment
failures” may not be distinguished from ADRs only based on data
without any prior knowledge. For example, the promotility drugs, in-
cluding cisapride, metoclopramide, and domperidone in Table I, are
reserved either for patients who do not respond to other treatments or
are added to enhance other treatments for gastroesophageal reflux disease
(see http://www.medicinenet.com/gastroesophageal_reflux_disease_gerd/
page6.htm). Thus, it is not surprising to see that there are still many patients
suffering esophagitis after taking these drugs. These are not ADRs but
“treatment failures” according to our medical experts.
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TABLE II
SOME DRUGS STRONGLY ASSOCIATED WITH Esophagitis GENERATED BY OPUS_AR+ FOR OLDER FEMALE PATIENTS
TABLE III
TOP TEN DRUGS UNEXPECTEDLY ASSOCIATED WITH Hepatitis SHORTLISTED BY MUTARC FOR THE MIDDLE-AGED FEMALE PATIENTS (THE BOLD AND THE
SLANTED ROWS ARE FOR Nefazodone AND Flucloxacillin, RESPECTIVELY)
TABLE IV
SOME DRUGS ASSOCIATED WITH Hepatitis GENERATED BY THE OPUS_AR+ FOR THE MIDDLE-AGED FEMALE PATIENTS
the OPUS_AR+ . Eleven patients suffer hepatitis soon after
taking nefazodone. Thus, the support for the UTAR nefa-
zodone
T
↪→ hepatitis is as low as 0.05%. Its residual-leverage
is 3.78× 10−4 , and it is ranked 3 among 758 different kinds of
drugs. As a comparison, the OPUS_AR+ ranks the TAR ne-
fazodone T→ hepatitis as low as 25. It is worth pointing out
that rank 4 in Table III indicates another very interesting ADR
ﬂucloxacillin
T
↪→ hepatitis. The algorithm designers and exper-
iment runners have not been aware of this ADR before medi-
cal experts checked the experimental results. According to the
Australian Adverse Drug Reactions Bulletin,ﬂucloxacillin is the
most commonly reported to the Adverse Drug Reactions Advi-
sory Committee (ADRAC) in association with hepatic reaction
up to March 1996 [30]. As a comparison, the OPUS_AR+ ranks
this association as low as 20 in Table IV. On the other hand, the
runtime of the MUTARC and OPUS_AR+ is 18.6 and 18.3 s,
respectively.
Table V lists the top ten suspected drugs that unexpectedly
lead to angioedema generated by the MUTARC, while Table VI
lists some drugs strongly associated with angioedema gener-
ated by the OPUS_AR+ . The runtime of the two algorithms
is 1.9 and 1.8 s, respectively. Interestingly, there is only one
ACE inhibitor, lisinopril (C09AA03), among the top ten drugs
strongly associated with angioedema in Table VI. However,
three from nine distinct ACE inhibitors, i.e., lisinopril, perindo-
pril (C09AA04), and fosinopril (C09AA09) are within the top
ten drugs shortlisted by the MUTARC. They are ranked 1, 8,
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TABLE V
TOP TEN DRUGS UNEXPECTEDLY ASSOCIATED WITH Angioedema SHORTLISTED BY THE MUTARC FOR THE OLDER FEMALE PATIENTS (THE THREE BOLD ROWS
ARE FOR THREE DISTINCT ACE Inhibitors)
TABLE VI
SOME DRUGS ASSOCIATED WITH Angioedema GENERATED BY THE OPUS_AR+ FOR THE OLDER FEMALE PATIENTS
TABLE VII
TOP TEN DRUGS UNEXPECTEDLY ASSOCIATED WITH Angioedema SHORTLISTED BY THE MUTARC FOR THE OLDER MALE PATIENTS (THE TWO BOLD ROWS ARE
FOR TWO DISTINCT ACE Inhibitors)
and 9, respectively. In addition, these ranks are much higher
than their ranks in terms of leverage. For example, the rank of
fosinopril improves from 48 to 9. Even for lisinopril, its rank
advances from 2 to 1. Again paracetamol is ranked 9 based on
leverage, but as low as 211 based on residual-leverage.
Similar comparison results can be found for older-males with
respect to angioedema, as shown in Tables VII and VIII. For
example, lisinopril, enalapril (C09AA02), and codeine with
paracetamol (N02AA59) are ranked as, respectively, 1, 7, and
92 by the MUTARC and 7, 16, and 1 by the OPUS_AR+ . The
runtime of the two algorithms is 1.3 and 1.2 s, respectively. It is
interesting to point out that enalapril is shortlisted for the older
male stratum, not for the older female stratum, partially because
this drug was more carefully prescribed to females (because it
should not be used in pregnancy or lactation) [29]. Since only
several patients were prescribed perindopril and fosinopril , the
MUTARC could not shortlist these two drugs for this relatively
small stratum.
In summary, the MUTARC can shortlist six known ADRs
such as alendronate T↪→ esophagitis, nefazodone T↪→ hepati-
tis, lisinopril
T
↪→ angioedema, perindopril T↪→ angioedema,
fosinopril
T
↪→ angioedema, and enalapril T↪→ angioedema
within the ten most interesting UTARs. It can also high-
light another ADR, ﬂucloxacillin T↪→ hepatitis, which is
unknown to our algorithm designers and experiment run-
ners. In addition, it performs much more effectively than the
OPUS_AR+ , which is implemented and parameterized same
as the MUTARC except without the case-based exclusion
operation.
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TABLE VIII
TOP DRUGS ASSOCIATED WITH Angioedema GENERATED BY THE OPUS_AR+ FOR THE OLDER MALE PATIENTS
TABLE IX
RANKS OF THE SUSPECTED DRUGS GENERATED BY THE MUTARC AND OPUS_AR+ FOR 18 DIFFERENT PARAMETER SETTINGS
C. Reliability Examination
It is important to study the influence of the different parameter
settings of the MUTARC on the performance of the ADR signal
generation [9]. This shows the reliability of the algorithm. For
simplicity, we take the three ADRs, alendronate T↪→ esophagi-
tis, nefazodone
T
↪→ hepatitis, and ﬂucloxacillin T↪→ hepatitis,
as examples to illustrate its reliable performance.
Besides using the specific age-gender strata, as in
Section IV-B, we also examined our algorithm on all the strata
for a given diagnosis, as shown in the first column of Table
IX. We used two different approaches to choose the noncase
subsequences:
1) Using matched control period: for each case, a prespecified
number (e.g., 6 for esophagitis patients and 21 for hepatitis
patients) of different noncases are selected as those who have a
hospitalization event in the month of the first occurrence of the
consequent in the case and are in the same age-gender stratum
as the case and
2) Using random control period: where a Tc -sized subse-
quence is chosen randomly from each noncase sequence within
[tS − Tc, tE ]. Various hazard period lengths Th were tested such
as 180, 120, 90, and 60 d. We also set different study periods
such as from 550 to 1645, 730 to 1645, and 910 to 1645, as
shown in the fourth column of Table IX. Note that Tb = 365 by
default, tS = 550 was the minimal value we might choose in
order to have at least half-a-year time period available for the
reference period.
For the older female patients, the ranks of alendronate based
on residual-leverage with respect to esophagitis range from
4 to 9 for the nine different parameter settings. The average
rank is 6.7. The ranks based on leverage range from 27 to 41,
which lie at least 21 behind. On average, they lie 25.9 behind.
Similarly, for middle-aged-female patients, the ranks of nefa-
zodone
T
↪→ hepatitis generated by the MUTARC range from
1 to 8. The average is 5.2. The ranks of nefazodone T→ hep-
atitis generated by the OPUS_AR+ are from 16 to 45, and the
MUTARC sorts this ADR 15 to 37 higher than the OPUS_AR+
does. The ranks of ﬂucloxacillin T↪→ hepatitis generated by the
MUTARC range from 3 to 16. The average is 7.3. The ranks
of ﬂucloxacillin T→ hepatitis generated by the OPUS_AR+ are
from 12 to 34, and the MUTARC ranks the ADR 7 to 18 higher
than the OPUS_AR+ does.
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If all the strata are included, the ranks of alendronate T↪→
esophagitis range from 16 to 20, while those of alendronate
T→ esophagitis vary from 62 to 119. Ranks generated by the
MUTARC are 46 to 100 higher than those generated by the
OPUS_AR+ , and 64.3 higher on average. The ranks of nefa-
zodone
T
↪→ hepatitis are from 10 to 20, and those of nefa-
zodone T→ hepatitis are from 36 to 62. The MUTARC ranks
this association at least 24 higher than the OPUS_AR+ . Simi-
larly, the ranks of ﬂucloxacillin T↪→ hepatitis generated by the
MUTARC range from 9 to 23, and those of ﬂucloxacillin T→ hep-
atitis generated by the OPUS_AR+ are from 16 to 38. The MU-
TARC ranks the association 8.3 higher than the OPUS_AR+ on
average. In a word, the MUTARC stably ranks the three ADRs
within the top ten for their risky age-gender strata of patients,
and within the top 20 for all strata, for almost all the different
parameter settings. The only exception is for the association
between ﬂucloxacillin andhepatitiswhen Th = 60. It is worth
noting that the MUTARC reliably shortlisted alendronate T↪→
esophagitis based on the data up to June 1999, while this ADR
has not been announced until August 1999 in Australia [28].
That illustrates that our techniques can be used to signal ADRs
promptly.
V. RELATED WORK
Our work is closely related to the problem of mining TARs
where a consequent and an antecedent occur together frequently
within a data subset specified by temporal constraints. Along
this direction, Li et al. [3] studied TARs during time intervals
specified by a user-given calendar schema. Lee et al. [2] ex-
plored the problem of mining TARs in publication databases
where time intervals rather than timestamps were used. Harms
and Deogun [31] also presented an efficient method for finding
frequent TARs in one or more sequences that precede the occur-
rence of patterns in other sequences. Different from TARs, as
a new knowledge representation, our proposed UTAR A T↪→C
indicates the antecedent A unexpectedly occurs within a T-sized
period prior to the consequent C.
Our pairwise UTARs can also be viewed as sequential patterns
[4] (or episodes in [5]), where a collection of events occur
relatively close together in a given partial order. There were
several efficient algorithms on searching for sequential patterns
that were more frequently than a threshold [4], [6], or were
further constrained [5]. For example, Sun et al. [23] discussed
the discovery, from a single sequence, of negative event-oriented
associations in which the antecedent patterns happen frequently
all the time but before the consequent.
Clearly, all these techniques concentrate on finding frequent
sequential patterns/itemsets. They are not suitable for identify-
ing infrequent unanticipated episodes like ADRs, which is the
main aim of this work. The existing techniques consider differ-
ent aspects of temporal data mining; we consider our research
as complementary to them.
The problem of discovering user’s unexpected rules, ex-
plored by Wang et al. [25], is closely related to our work.
It concentrated on how to embed the user knowledge in the
association rule mining procedure, and established promising
techniques to find more unexpected associations of user inter-
est [25]. In many areas, such as medication, there is too much do-
main knowledge to be considered. Furthermore, the user knowl-
edge is not always easily available, as pointed out in [25]. In
contrast, our solution is to better use the data and automati-
cally degrade the uninteresting associations during the mining
procedure.
Keogh et al. proposed efficient techniques, from a time series,
for finding unusual subsequences that are maximally different
to all the rest of time-series subsequences [32]. Differing from
sequential patterns and UTARs, these unusual subsequences
only contain contiguous events.
In the medical domain, current postmarket ADR signaling
techniques like proportional reporting ratios (PRRs) [9], multi-
item Gamma Poisson Shrinker (MGPS) [14], and Bayesian
confidence propagation neural network (BCPNN) [33] perform
fruitfully on spontaneous ADR case reports [9]. Each ADR
case report describes the suspected causality between drugs and
conditions for one patient. Thus, different from the MUTARC,
these techniques are not suitable for healthcare administrative
data that only routinely record drugs and conditions for people
accessing a healthcare system. Other ADR monitoring systems,
as reviewed in [12], are to identify adverse events by searching
for given ADRs like drug-possibly-causing-symptom patterns.
From healthcare administrative databases, risk patterns [13] may
find patient groups at high risk of a given adverse reaction. The
ADR signals shortlisted by our proposed techniques can help
these systems move toward automation.
VI. CONCLUSION AND DISCUSSION
Mining unanticipated episodes is of great application value.
For example, ADR signals generated can be used, after valida-
tion, to prevent lots of unnecessary conditions or hospitalization
worldwide. In order to discover unanticipated episodes, in this
paper, we have introduced a knowledge representation, UTARs,
and an interestingness measure, residual-leverage. Based on the
novel case-based exclusion and event-oriented data preparation
techniques, we have developed an effective mining algorithm,
the MUTARC, to discover infrequent pairwise UTARs. The
MUTARC has been applied in signaling ADRs from health-
care administrative databases. It has reliably shortlisted with
various parameter settings, not only the known ADRs, but also
an unknown ADR to algorithm designers and experiment run-
ners. It has empirically performed much more effectively than
the OPUS_AR+ whose only difference from the MUTARC is
without the case-based exclusion operation. These experimental
results have illustrated a new promising direction of ADR sig-
nal generation based only on linked healthcare administrative
databases. This has also justified the usefulness of our proposed
techniques.
We have only concentrated on highlighting pairwise UTARs
in this paper. However, the proposed concept and its interest-
ingness measure are readily extended to detect more sophisti-
cated UTARs. Another possible extension is to consider some
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quantitative information such as dosage of drug usage during
exclusion in order to discover unanticipated episodes such as
conditions induced by cumulative drug toxicity. One general
way for mining unexpected temporal associations is to use a
data mining algorithm to find some expected temporal associa-
tions from data directly, and then, using this mined knowledge
to help us discover unexpected ones. These research directions
are the subject of our future work.
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